Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2011-04-26
2011-04-26
Gussow, Anne M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S193100, C514S002600
Reexamination Certificate
active
07931904
ABSTRACT:
The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either p53 or TBP. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of MUC1 by a cell.
REFERENCES:
patent: 5565334 (1996-10-01), Kufe et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5874415 (1999-02-01), Kufe et al.
patent: 6093573 (2000-07-01), Beamer et al.
patent: 6613883 (2003-09-01), Harris et al.
patent: 7247297 (2007-07-01), Weichselbaum et al.
patent: 2002/0110841 (2002-08-01), Kufe
patent: 2004/0018181 (2004-01-01), Kufe et al.
patent: 2004/0166543 (2004-08-01), Kufe
patent: 2005/0015232 (2005-01-01), Reinherz et al.
patent: 2005/0042209 (2005-02-01), Kufe et al.
patent: 2005/0053606 (2005-03-01), Kufe et al.
patent: 2005/0169898 (2005-08-01), Gong et al.
patent: 2005/0238627 (2005-10-01), Ohno et al.
patent: 2007/0105767 (2007-05-01), Kharbanda et al.
patent: 2007/0141704 (2007-06-01), Nicolette et al.
patent: 2007/0202134 (2007-08-01), Kufe et al.
patent: WO 00/09744 (2000-02-01), None
patent: WO 00/11206 (2000-03-01), None
patent: WO 00/47763 (2000-08-01), None
patent: WO 2004/092339 (2004-10-01), None
Asada et al., “Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation.,”EMBO J., 18:1223-1234, 1999.
Barlev et al., “Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases,”Mol. Cell, 8:1243-1254, 2001.
Barrios et al., “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming,”Eur. J. Immunol., 22:1365-1372, 1992.
Brody et al., “Aptamers as therapeutic and diagnostic agents,”Reviews in Molecular Biotechnology, 74:5-13, 2000.
Chao et al., “p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage,”Embo J., 19:4967-4975, 2000.
Cristiano et al., “Molecular conjugates: a targeted gene delivery vector for molecular medicine,”J. Mol. Med., 73:479-486, 1995.
Dong et al., “Cytosolic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells,”Cell Signal, 16:263-269, 2004.
Dupont et al., “The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells,”J. Biol. Chem., 278:37256-37264, 2003.
Duraisamy et al., “Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 and MUC16,”Gene, 373:28-34, 2006.
El-Deiry et al., “WAF1, a potential mediator of p53 tumor suppression,”Cell, 75:817-825, 1993.
Flores et al., “p63 and p73 are required for p53-dependent apoptosis in response to DNA damage,”Nature, 416:560-564, 2002.
Gendler et al., “A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats,”J. Biol. Chem., 263:12820-12823, 1988.
Gronenborn et al., “Protein structure determination in solution by two-dimensional and three-dimensional nuclear magnetic resonance spectroscopy,”Anal. Chem., 62(1):2-15, 1990.
Hsieh et al., “Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage,”Mol. Cell. Biol., 22:78-93, 2002.
Huang et al., “MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation,”Cancer Biol. Ther., 2:702-706, 2003.
Hudson et al., “High avidity scFv multimers; diabodies and triabodies,”J. Immunol. Methods, 231(1-2):177-189, 1999.
Huston et al., “Engineered antibodies take center stage,”Hum. Antibodies, 10(3-4):127-142, 2001.
J. Cavanagh et al.,Protein NMR Spectroscopy, Principles and Practice, Academic Press, San Diego, 1996.
Jack et al., “Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response,”Proc. Natl. Acad. Sci. USA, 99:9825-9829, 2002.
Jimenez et al., “A transactivation-deficient mouse model provides insights into Trp53 regulation and function,”Nat. Genet., 26:37-43, 2000.
Kaeser et al., “Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo,”Proc. Natl. Acad. Sci. USA, 99:95-100, 2002.
Kufe et al., “Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors,”Hybridoma, 3:223-232, 1984.
Levine, “p53, the cellular gatekeeper for growth and division,”Cell, 88:323-331, 1997.
Li et al., “Human DF3/MUC1 carcinoma-associated protein functions as an oncogene,”Oncogene, 22(38):6107-10, 2003.
Li et al., “Interaction of human MUC1 and beta-catenin is regulated by Lck and ZAP-70 in activated Jurkat T cells,”Biochem. Biophys. Res Commun., 315(2):471-6, 2004.
Li et al., “DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7 ,”Cancer Biol. Ther., 2:187-193, 2003.
Li et al., “Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein,”Mol. Cancer Res., 1:765-775, 2003.
Li et al., “The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin,”J. Biol. Chem., 276:35239-35242, 2001.
Li et al., “The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin,”J. Biol. Chem., 276:6061-6064, 2001a.
Li et al., “Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin,”Mol. Cell. Biol., 18:7216-7224, 1998.
Lightenberg et al., “Cell-associated episialin is a complex containing two proteins derived from a common precursor,”J. Biol. Chem., 267:6171-6177, 1992.
Liu et al., “The Activation Domains, the Proline-rich Domain, and the C-terminal Basic Domain in p53 Are Necessary for Acetylation of Histones on the Proximal p21 Promoter and Interaction with p300/CREB-binding Protein,”J. Biol. Chem., 278:17557-17565, 2003.
McPherson, “Crystallization of proteins from polyethylene glycol,”J. Biol. Chem., 251:6300-6306, 1976.
Merlo et al., “Frequent alteration of the DF3 tumor-associated antigen gene in primary human breat carcinomas,”Cancer Res., 49:6966-6971, 1989.
Miyashita et al., “Tumor suppressor p53 is a direct transcriptional activator of the human bax gene,”Cell, 80:293-299, 1995.
Mujtaba et al., “Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation,”Mol. Cell, 13:251-263, 2004.
Muller et al., “p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs,”J. Exp. Med., 188:2033-2045, 1998.
Oda et al., “p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53,”Cell, 102:849-862, 2000.
Oda et al., “Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis ,”Science, 288:1053-1058, 2000.
Oren, “Decision making by p53: life, death and cancer,”Cell Death Differ., 10:431-442, 2003.
Perey et al., “Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen,”Cancer Res., 52:2563-2568, 1992.
Poljak, “Production and structure of diabodies,”Structure, 2(12):1121-1123, 1994.
Raina et al., “MUC1 oncoprotein blocks nuclear targeting of c-Abl in the a poptotic response to DNA damage,”EMBO J., 25(16):3
Dana Farber Cancer Institute, Inc.
Fulbright & Jaworski
Gussow Anne M.
LandOfFree
Modulation of MUC1 activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of MUC1 activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of MUC1 activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631085